EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Treatment acceptability for disease‐modifying therapy for type 1 diabetes ( T1D )—Views from parents of children with presymptomatic T1D

Lauren M Quinn iD, Olga Boiko, Josephine Elliott, Matthew Randell, Ian Litchfield, Felicity Boardman, Renuka P Dias, Sheila M Greenfield, Parth Narendran

Diabetes, Obesity and Metabolism · 2025-10 · 27 (10) · 6059-6067

DOI: 10.1111/dom.16639 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.07.2025. Verfasst von Lauren M Quinn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, University of Birmingham, Brimingham, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabetes UK, Breakthrough T1D.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first disease-modifying therapy for type 1 diabetes (T1D), teplizumab, became available in 2022 in the US.1 Teplizumab is currently undergoing review for licensing in the UK and delays symptomatic onset and need for insulin by approximately two years in those with stage 2 presymptomatic T1D2, defined as multiple islet-specific autoantibody seropositivity and dysglycaemia on oral glucose tolerance testing.3 Teplizumab is administered by daily infusion over two weeks, as a single course of treatment. Both hospital setting and home infusion can be accommodated.1 The most common adverse event is a mild cytokine release syndrome including myalgia, fever, and rash2 which resolves with prophylactic, symptomatic management.1 Approximately 70% develop transient lymphopenia within 30 days of treatment which resolves without sequelae.2 Although appearing safe in the long-term, with more than six years surveillance data demonstrating no increased risk of infection or malignancy in this cohort of patients4, treatment comes at significant financial cost (both to healthcare systems and family) and requires absence from work and school5. Critically, the acceptability of teplizumab treatment has not been formally assessed via qualitative interviews anywhere in the world and we wanted to explore this to outline important considerations for clinicians to support shared decision-making should it be licensed in the UK. Here, we present the first qualitative data with parents/caregivers of stage 2 children, exploring views towards disease-modifying treatment.

Schlagwörter

Stichwörter der Autor:innen

attitudesbarriersdisease modifying therapyperceptionspreventiontype 1 diabetes

Autor:innen und Institutionen

  • Institute of Immunology and Immunotherapy, University of Birmingham, Brimingham, UK.
  • Department of Applied Health Sciences, University of Birmingham, Brimingham, UK.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Applied Health Directorate, University of Warwick, Warwick, UK.
  • Department of Paediatric Endocrinology, Birmingham Women and Children's Hospital, Birmingham, UK.
  • Department of Diabetes, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

ORCID-Profile: Lauren M Quinn

Förderung

  • Diabetes UK
  • Breakthrough T1D

Zitieren

APA

Quinn, L. M., Boiko, O., Elliott, J., Randell, M., Litchfield, I., Boardman, F., Dias, R. P., Greenfield, S. M., & Narendran, P. (2025). Treatment acceptability for disease‐modifying therapy for type 1 diabetes ( T1D )—Views from parents of children with presymptomatic T1D. Diabetes, Obesity and Metabolism, 27(10), 6059-6067. https://doi.org/10.1111/dom.16639

Vancouver

Quinn LM, Boiko O, Elliott J, Randell M, Litchfield I, Boardman F, et al. Treatment acceptability for disease‐modifying therapy for type 1 diabetes ( T1D )—Views from parents of children with presymptomatic T1D. Diabetes, Obesity and Metabolism. 2025;27(10):6059-6067. doi:10.1111/dom.16639

BibTeX
@article{Quinn2025,
  author = {Quinn, Lauren M and Boiko, Olga and Elliott, Josephine and Randell, Matthew and Litchfield, Ian and Boardman, Felicity and Dias, Renuka P and Greenfield, Sheila M and Narendran, Parth},
  title = {Treatment acceptability for disease‐modifying therapy for type 1 diabetes ( T1D )—Views from parents of children with presymptomatic T1D},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {10},
  pages = {6059--6067},
  doi = {10.1111/dom.16639}
}
Kostenlos starten →